

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3341292

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ABBOTT LABORATORIES	02/10/2015
RECEIVING PARTY DATA	
Name:	ZOETIS BELGIUM S.A.
Street Address:	1 RUE LAID BURNAIT
City:	LOUVAIN-LA-NEUVE
State/Country:	BELGIUM
Postal Code:	1348
PROPERTY NUMBERS Total: 7	
Property Type	Number
Application Number:	08779786
Application Number:	09137403
Application Number:	12636227
Application Number:	13817721
Application Number:	13818013
Application Number:	11356451
Application Number:	13327028
CORRESPONDENCE DATA	
Fax Number:	(703)739-2815
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	iprecordals@cpaglobal.com, gpillai1@cpaglobal.com
Correspondent Name:	CPA GLOBAL LIMITED
Address Line 1:	LIBERATION HOUSE
Address Line 2:	CASTLE STREET
Address Line 4:	ST HELIER, JERSEY JE1 1BL
NAME OF SUBMITTER:	HELEN BIRRELL
SIGNATURE:	/H/BIRRELL/IPR/GP/Zoetis (Abbott/AG7PT/
DATE SIGNED:	05/06/2015
Total Attachments: 7	


source=Deed of Assignment (3)#page1.tif
source=Deed of Assignment (3)#page2.tif
source=Deed of Assignment (3)#page3.tif
source=Deed of Assignment (3)#page4.tif
source=Deed of Assignment (3)#page5.tif
source=Deed of Assignment (3)#page6.tif
source=Deed of Assignment (3)#page7.tif

AFFIDAVIT

I, Barbara L. Renda, Attorney-in-Fact of Zoetis Belgium S.A., a Société Anonyme organized under the laws of Belgium, do hereby swear by virtue of my signature below, that:

1. I have access to the records of the company and am authorized to make this statement on behalf of the Company.
2. The attached is a true, complete and exact copy of the duly executed Patent Assignment between Abbott Laboratories and Zoetis Belgium S.A.


Zoetis Belgium S.A.

By: 

Name: Barbara L. Renda

Title: Attorney-in-Fact

Sworn to before me this 27th day of April, 2015.


Notary Public

Luzma E. Droz
NOTARY PUBLIC OF NEW JERSEY
My Commission Expires May 2, 2018



PATENT ASSIGNMENT

This PATENT ASSIGNMENT (this "Patent Assignment") effective as of February 10, 2015, by and between Abbott Laboratories, an Illinois corporation ("Assignor") and Zoetis Belgium S.A., a *société anonyme* organized under the Laws of Belgium ("Assignee"). Assignor and Assignee may be referred to herein collectively as the "Parties" and individually as a "Party".

WHEREAS, Assignor and Assignee have entered into that certain Asset Purchase Agreement, dated as of November 16, 2014 (the "Asset Purchase Agreement"), pursuant to which the Assignor has agreed to sell to Assignee all of Assignor's right, title and interest in and to, among other things, the Owned Intellectual Property (as defined in the Asset Purchase Agreement), including the Assigned Patents (as defined below); and

WHEREAS, Assignor and Assignee desire to execute this Patent Assignment for purposes of, among other things, recording the assignment of the Assigned Patents and filing this Patent Assignment with the United States Patent and Trademark Office and/or any other applicable intellectual property offices and/or similar agencies outside of the United States, as may be necessary to effectuate the assignment of the Assigned Patents.

NOW, THEREFORE, intending to be legally bound and in consideration of the mutual provisions set forth in this Patent Assignment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. Assignment. Assignor has assigned and/or by these presents does hereby assign, transfer, and convey unto Assignee all of Assignor's right, title, and interest in and to the Owned Intellectual Property, including:

(a) the patents, patent applications, statutory invention registrations, utility models, utility model applications, petty patents, provisionals, non-provisionals, design patents and certificates of invention and patent disclosures, together with all reissues, continuations, continuations-in-part, divisions, revisions, extensions, restorations and reexaminations thereof, as specifically listed in Schedule A (collectively, the "Assigned Patents");

(b) all rights pertaining to any of the foregoing arising under international treaties and convention rights;

(c) the right and power to assert, defend and recover title to any of the foregoing;

(d) all rights to assert, defend and recover for any past, present and future infringement, misuse, misappropriation, impairment, unauthorized use or other violation of any of the foregoing; and

(e) all administrative rights arising from the foregoing, including the right to prosecute applications and oppose, interfere with or challenge the applications of others, the rights to obtain renewals, continuations, divisions, and extensions of legal protection pertaining to any of the foregoing.

2. Terms of the Asset Purchase Agreement. This Patent Assignment is subject in all respects to the terms and provisions of the Asset Purchase Agreement. In the event of any conflict or inconsistency between the terms of the Asset Purchase Agreement and the terms hereof, the terms of the Asset Purchase Agreement shall govern.

3. Assistance. Assignor shall use commercially reasonable efforts, upon Assignee's request therefor, to provide reasonable assistance and execute and deliver such documents and other papers and any other agreements, as may be necessary, proper or advisable to carry out the provisions of this Patent Assignment, including, as may reasonably be necessary, proper or advisable to secure the vesting in Assignee of, and to perfect, preserve, register and record Assignee's rights in and to, all rights assigned to Assignee by this Patent Assignment, including any assistance or documents required to record this Patent Assignment with the United States Patent and Trademark Office and/or any other applicable intellectual property offices and/or similar agencies outside of the United States.


4. Miscellaneous. The provisions of Article 13 of the Asset Purchase Agreement shall apply to this Agreement, *mutatis mutandis*.

IN WITNESS WHEREOF, each of the Parties has executed this Patent Assignment, or has caused this Patent Assignment to be executed on its behalf by a representative duly authorized, all as of the date first above set forth.



ABBOTT LABORATORIES

By: _____
Name: Paul D. Yasger
Title: Assistant Secretary



Karen R. Smith

NOTARY:

Witness


Name: *Susan L. Yare*

Name: *Vicki L. Funches*

Signature: *Susan L. Yare*

Signature: *Vicki L. Funches*

ZOETIS BELGIUM S.A.

By: 
Name: Barbara A. Smith
Title: Authorized Representative

NOTARY: Christine A. Apennin
Notary Public, State of New York
12-20-18

Witness
Name: Regina Brown

Signature: Regina Brown

Name: Doreen Smith

Signature: Doreen Smith

SCHEDULE A

I. ASSIGNED PATENTS

(A) Patents constituting Owned Intellectual Property

Case Ref. No.	App. No.	App. Date	Patent No.	Grant Date	Country	Title
10556AU01	2012291462	8/19/2011			Australia	Anti NGF Antibodies And Their Use
10556CA01	2808577	8/19/2011			Canada	Anti NGF Antibodies And Their Use
10556EPO1	11767319.4	8/19/2011			European Patent	Anti NGF Antibodies And Their Use
10556HK01	13114247.7	8/19/2011			Hong Kong	Anti NGF Antibodies And Their Use
10556JPO1	2013-525008	8/19/2011			Japan	Anti NGF Antibodies And Their Use
10556US01	13817721	8/19/2011			United States	Anti NGF Antibodies And Their Use
10556WO01	PCT/US2011/048518	8/19/2011			Patent Cooperation Treaty	Anti NGF Antibodies And Their Use
10649AU01	2011295594	9/2/2011			Australia	High Dose Buprenorphine Compositions And Methods Of Use
10649CA01	2008037	9/2/2011			Canada	High Dose Buprenorphine Compositions And Methods Of Use
10649EPO1	11758027.4	9/2/2011			European Patent	High Dose Buprenorphine Compositions And Methods Of Use
10649JPO1	2013-527354	9/2/2011			Japan	High Dose Buprenorphine Compositions And Methods Of Use
10649US01	13818013	9/2/2011			United States	High Dose Buprenorphine Compositions And Use As Analgesic
10649WO01	PCT/US2011/050413	9/2/2011			Patent Cooperation Treaty	High Dose Buprenorphine Compositions And Methods Of Use
11979AU01	2012200031	1/3/2012	2012200031	12/19/2013	Australia	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979AU02	2013263787	11/28/2013			Australia	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979AU01	2006214166	2/17/2006	2006214166	1/13/2012	Australia	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979CA01	2818963	7/3/2013			Canada	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979CA01	2587966	2/17/2006	2587966	7/9/2013	Canada	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979DE01	06735301.1	2/17/2006	602005041571.7	5/21/2014	Germany	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979EP01	14163319.6	4/3/2014			European Patent	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979EPO1	06735301.1	2/17/2006	1948270	5/21/2014	European Patent	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979ES01	06735301.1	2/17/2006	1848270	5/21/2014	Spain	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979FR01	06735301.1	2/17/2006	1848270	5/21/2014	France	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979GB01	06735301.1	2/17/2006	1848270	5/21/2014	Great Britain	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals

Case Ref. No.	App. No.	App. Date	Patent No.	Grant Date	Country	Title
11979ITC1	06735301.1	2/17/2006	1846270	5/21/2014	Italy	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979JPD1	2012-271386	12/12/2012			Japan	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979JPO1	2007-556306	2/17/2006			Japan	Transmucosal Administration Of Drugs For Treating And Preventing Disorders In Animals
11979JSC1	13027028	12/15/2011			United States	Transmucosal Administration Of Meloxicam Compositions For Treating And Preventing Disorders In Non-Human Domesticated
11979JSC1	11058451	2/17/2006	8097614	1/17/2012	United States	Treating and Preventing Disorders in Non-Human Domesticated
5828USP1	08779766	1/7/1997	6274715	8/14/2001	United States	Trocydic Erythromycin Derivatives
6169MXO1	PA/91999/011772	8/20/1998	236453	5/3/2006	Mexico	Prostaglandin Endoperoxide H Synthase Biosynthesis Inhibitors
6169JSC2	09137403	8/20/1998	6525053	2/25/2003	United States	Prostaglandin Endoperoxide H Synthase Biosynthesis Inhibitors
8666JSC1	12636227	12/11/2009	8435508	6/4/2013	United States	Sustained Release Parenteral Formulations Of Buprenorphine